Clinical Patient trial starting soon
We are currently preparing to start our first clinical trial with the injectable hydrogel technology. This trial will be conducted at selected medical centers in the Netherlands. The focus of the trial is to evaluate the safety and performance of our technology for the repair of cartilage defects in the knee.
The trial will be led by dr. R.J.H. Custers, orthopedic surgeon, department of orthopedics of the University Medical Center Utrecht as the Principal Investigator (https://www.umcutrecht.nl/nl/ziekenhuis/zorgverleners/custers-rjh).
Trial expected to start after the summer of 2021
The injectable hydrogel is an investigational implant designed for patients who are suffering from a relatively recent cartilage injury surrounded by healthy cartilage. It is NOT aimed at advanced stages of cartilage disease like OsteoArthritis or Rheumatoid Arthritis.
Hy2Care’s injectable hydrogel has not yet been approved by regulatory authorities for commercial sale and can only be used in a clinical study.